Avelumab (Bavencio®). HTA ID: 21001

Assessment Status NCPE Assessment Process Complete
HTA ID 21001
Drug Avelumab
Brand Bavencio®
Indication As monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma whose disease has not progressed with first line platinum-based induction chemotherapy.
Assessment Process
Rapid review commissioned 25/01/2021
Rapid review completed 03/03/2021
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of avelumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 24/03/2021
Pre-submission consultation with Applicant 20/04/2021
Full submission received from Applicant 10/06/2021
Preliminary review sent to Applicant 28/09/2021
NCPE assessment re-commenced 22/10/2021
Factual accuracy sent to Applicant 29/11/2021
NCPE assessment re-commenced 06/12/2021
NCPE assessment completed 22/12/2021
NCPE assessment outcome The NCPE recommends that avelumab (Bavencio®), for first-line maintenance treatment of adult patients with bladder cancer who are disease free following platinum-based chemotherapy, not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations September 2022.